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A vexing problem in cystic fibrosis (CF) pathogenesis has been to
explain the high prevalence of Pseudomonas aeruginosa biofilms
in CF airways. We speculated that airway surface liquid (ASL)
hyperabsorption generates a concentrated airway mucus that
interacts with P. aeruginosa to promote biofilms. To model CF vs.
normal airway infections, normal (2.5% solids) and CF-like concen-
trated (8% solids) mucus were prepared, placed in flat chambers,
and infected with an 5  103 strain PAO1 P. aeruginosa. Although
bacteria grew to 1010 cfu/ml in both mucus concentrations, mac-
rocolony formation was detected only in the CF-like (8% solids)
mucus. Biophysical and functional measurements revealed that
concentrated mucus exhibited properties that restrict bacterial
motility and small molecule diffusion, resulting in high local bac-
terial densities with high autoinducer concentrations. These prop-
erties also rendered secondary forms of antimicrobial defense, e.g.,
lactoferrin, ineffective in preventing biofilm formation in a CF-like
mucus environment. These data link airway surface liquid hypera-
bsorption to the high incidence of P. aeruginosa biofilms in CF via
changes in the hydration-dependent physical–chemical properties
of mucus and suggest that the thickened mucus gel model will be
useful to develop therapies of P. aeruginosa biofilms in CF airways.
mucus  rheology
Cystic fibrosis (CF) lung disease reflects the chronic bacterialinfection of intrapulmonary airways with Pseudomonas
aeruginosa biofilms (1, 2). P. aeruginosa biofilms have mostly
been studied in flow chambers (3–7) that are good models for the
biofilms that form on venous or urethral catheters under con-
ditions of high flow rates and relatively high oxygen tensions.
However, biofilms in CF airways form in thickened (concen-
trated) mucus gels that are relatively hypoxic and adherent to
airway surfaces (see Fig. 1A) (8, 9). Recently, Sriramulu et al.
(10) investigated the role autoregulators and amino acids play in
the tightness of biofilm formation in a mucus stimulant of
constant hydration. For the present study, we designed a culture
system to investigate whether dehydration of the CF mucus
environment may predispose to P. aeruginosa biofilm formation.
A key aspect of the model was the selection of mucus
concentrations that mimic normal and CF mucus. Although
measurements of mucus concentration, i.e., the percentage of
solids content, from CF subjects before infection have not been
reported, estimates from cell cultures (11) and sputum (12–18)
suggest that CF mucus is at least three or four times more
concentrated than normal. Therefore, mucus was obtained from
well differentiated human airway cultures and was isotonically
concentrated (1) to produce mucus of normal (2.5% solids
wt/wt) and CF-like (8%) concentrations (Fig. 1B). Aliquots of
each were deposited in (i) an open chamber to model a mucus
plaque adherent to CF airway surfaces with a residual lumen
allowing airf low and (ii) a closed chamber to mimic a mucus plug
occluding a CF airway (Fig. 1 A). P. aeruginosa [PAO1 strain
stably expressing green fluorescent protein (GFP-PAO1)] was
then deposited in 1-l droplets (5  103 cfu) into mucus of the
two concentrations to mimic the aerosol droplet infection that is
thought to transmit P. aeruginosa in vivo.
Results
P. aeruginosa Growth and Growth Patterns in 2.5% vs. 8% Mucus. P.
aeruginosa grew and within 48 h reached the stationary phase at
1010 cfu/ml for 2.5% and 8% mucus in both open and closed
chambers (Fig. 1C). In closed chambers, pO2 plunged below 5%
9 h after bacterial inoculation and remained low. In open
chambers, pO2 remained higher in 2.5% mucus but was 5% at
24 h in 8% mucus (Fig. 1D). These data suggest that P. aeruginosa
grew well in human airway mucus under hypoxic as well as
normoxic environments, as previously reported (9, 19).
However, the growth pattern of P. aeruginosa (GFP-PAO1)
was distinctly different in 2.5% vs. 8% mucus (Fig. 2). Epiflu-
orescence and confocal microscopy studies of the open-chamber
model of CF airway mucus plaques revealed that P. aeruginosa
grew as macrocolonies within 8% mucus gels (Fig. 2 B and D).
These macrocolonies contained both live and dead cells, and
some macrocolonies exhibited band-like patterns of live and
dead cells (Fig. 2E). In contrast, no macrocolonies were detected
within 2.5% mucus gels, and only small bacterial aggregations
were observed on the plastic surface (Fig. 2 A and C). To
estimate colony volume, the total f luorescence intensity of P.
aeruginosa colonies was measured and was significantly greater
in 8% mucus than in 2.5% mucus (Fig. 2Fi). Importantly, the
difference in the colony size between 2.5% mucus and 8% mucus
was not due to bacterial growth (number of bacteria, Fig. 1C) but
was due to growth pattern (planktonic vs. macrocolony).
In the closed-chamber model of mucus plugs, intramucus
macrocolonies were again detected in 8% mucus, whereas in
2.5% mucus, small colonies were only detected on plastic
surfaces (not shown). The size of the macrocolonies developed
in 8% mucus was smaller than in open chambers (Fig. 2Fii),
suggesting that oxygen supply can affect macrocolony dimen-
sions, in agreement with previous studies (9).
Because it is possible that CF mucus exhibits features other
than increased concentration that promote biofilm formation,
we studied 2.5% and 8% mucus from CF cultures. In both the
open and closed systems, macrocolonies again were found in 8%
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but not in 2.5% CF mucus (Fig. 3A), suggesting that the
concentration of mucus, rather than the source, was the critical
variable. These data are consistent with previous data demon-
strating no differences in the biochemical properties between the
CF vs. normal mucins, the major component of mucus (20).
Development of P. aeruginosa biofilms is known to require the
LasR-LasI quorum sensing system (4). To test whether the
macrocolonies observed in airway surface liquid (ASL) were
biofilms rather than loose aggregates of bacteria with low
motility, we incubated lasI mutants of PAO1 in 8% mucus. These
lasI mutants grew similarly to wild-type PAO1 in 8% mucus
(1010 cfu/ml) (data not shown). x–y and x–z scanning confocal
microscopy demonstrated planktonic single lasI mutant bacteria,
but not macrocolonies, within 8% mucus (Fig. 3B iii and iv). The
macrocolony phenotype was rescued with the addition of 10 M
N-(3-oxododecanoyl)-L-homoserine lactone (3-oxo C12 HSL) to
8% mucus (Fig. 3Bv). These data demonstrate that the macro-
colonies in 8% mucus gels share genetic features with biofilms
studied in other systems.
Biophysical Properties of Mucus Gels. What is unique about an 8%
vs. 2.5% mucus gel? The predominant macromolecules in airway
mucus are the high-molecular-weight mucin polymers. These
polymers form a gel-like mesh in ASL that exhibits an apparent
mesh pore width and viscoelastic properties as a function of their
concentration. We used a microbead rheological technique that
probes an environment in which tracer particles are placed by
tracking their thermally driven Brownian motion to characterize
the biophysical (mesh, viscoelastic) properties of 8% vs. 2.5%
mucus gels. This method provides an excellent insight into the
physical environment observed by micrometer-sized particles
(21–26) and, thus, is an appropriate method to characterize the
environment experienced by P. aeruginosa [0.5  1.5 m (27)].
Fig. 1. Growth of P. aeruginosa strain PAO1 in model systems for mucus
plaques and plugs in CF airways. (A) Bacterial culture chambers mimicking
mucus plaques and plugs of CF airways. (i) Plaque of thickened mucus covering
a CF airway surface was mimicked with mucus placed in a 1-mm-deep plastic
chamber in a humidified Petri dish, open to oxygen supply from the lumen
(inset). (ii) Mucus plugs in CF airways were mimicked with mucus placed in a
1- mm-deep chamber with a plastic lid sealing the top to limit oxygen supply
(inset). (B) Composition of 2.5% and 8% mucus samples. Mucin concentration
was measured in normal (2.5% solids) and CF-like (8% solids) mucus by
differential refractometry. Other molecules are defined as DNA, cellular de-
bris, and other proteins [unpublished data from the Sheehan laboratory
(University of North Carolina)]. (C) Bacterial growth curve in normal and
CF-like mucus. Approximately 5  103 P. aeruginosa (PAO1) were deposited
onto 2.5% and 8% solid mucus in open (i) and closed (ii) chambers. Bacterial
number was counted at 0, 6, 24, 48, and 72 h; n  3. (D) Oxygen partial pressure
of P. aeruginosa-infected mucus. Oxygen partial pressure was measured at the
bottom of bacterial cultures with oxygen-sensitive fluorescent probe; n  5.
Fig. 2. P. aeruginosa macrocolony formation in mucus. (A–D) Bacteria
GFP-PAO1 (5  103) were deposited into mucus of 2.5% solids (A and C) and
8% solids (B and D) placed in open chambers and photographed on days 1, 2,
and 3 by epifluorescence (A and B) (10 objective) and x–z confocal (C and D)
(40 objective) microscopy. (Scale bars  200 m in A and C and 50 m in B and
D.) Representative of n  10 experiments. (E) Live and dead staining of P.
aeruginosa macrocolonies. Pseudomonas macrocolonies in 8% mucus were
photographed with x–y (i) and x–z (ii) scanning by confocal microscopy
(green  GFP, red propidium iodide). (Scale bar  50 m.) (F) Quantitation of
macrocolony size. Macrocolony size was expressed as the total fluorescence
intensity of a single macrocolony, reflecting the number of bacteria forming
a macrocolony. (i) open chamber, (ii) closed chamber; n  3.
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The thermally driven motion of microbeads greatly depends
on the percentage of solids of the mucus sample in which they
diffused. At the long time scales (5 sec), the means squared
displacement curve, r2, of 1-m beads is 50 times greater in
2.5% mucus than in 8% mucus (Fig. 4A). The slope of the means
squared displacement curve,  (see Methods), indicates that the
fluid is liquid-like (purely viscous) when   1 and is solid-like
(purely elastic) when   0. In 8% mucus,  was 0.2, whereas
in 2.5% mucus,  was 0.8 (Fig. 4A), suggesting that the 8%
mucus is highly elastic in nature.
Tracking motion of beads of varying sizes provides informa-
tion about the mesh properties of mucus (28, 29). In 2.5% mucus,
200-nm beads diffused over much greater distances than in 1-
and 3-m beads, even when corrected for bead radius (Fig. 4B).
These results indicate that the effective ‘‘mesh size’’ within the
2.5% mucus is between 0.2 and 1 m. In 8% mucus, all three
bead sizes were effectively trapped (Fig. 4B), indicating that all
were trapped in a tight mesh smaller than 200 nm. This tighter
mesh is also reflected in the decreased slope of the means
squared displacement curve for 8% mucus in Fig. 4A.
Interaction of P. aeruginosa with Mucus Gel. We tested predictions
from the biophysical characterization of mucus in a series of
microbiological experiments. First, consistent with analyses
of mesh size and bead motility, swimming (flagellar) motility of
PAO1 was found to be greatly reduced in 8% vs. 2.5% mucus
(Fig. 4C). Second, consistent with a measured mesh size of 0.2–1
m, an immobile PAO1 mutant (without pili and flagella) placed
in 2.5% mucus sedimented out of mucus onto the plastic surface
(data not shown). Third, it is predicted that small molecules
(much smaller than mesh size) will have equivalent diffusion in
both mucus concentrations. However, 3-oxo C12 HSL (estimated
to be smaller than 1 nm) diffused 10 times more slowly in 8%
mucus vs. 2.5% mucus (calculated diffusion coefficient was 4.8 
1010 m2/s in 2.5% mucus and 4.9  1011 m2/s in 8% mucus)
(Fig. 4D). We speculate that the slower diffusion reflects either
increased interactions between the hydrophobic 3-oxo C12 HSL
molecules and the hydrophobic sites of the mucin mesh or HSL
binding to mobile proteins larger than mesh size.
Effect of Mucus Gel on Soluble Innate Defense Molecules. Finally, we
asked whether there were unique aspects of thickened mucus
that allow P. aeruginosa macrocolonies to evade soluble second-
ary-defense mechanisms that protect airway surfaces. Because of
reports that lactoferrin was effective in inhibiting P. aeruginosa
biofilm formation in well oxygenated, f low-through abiotic
chamber surfaces (7), we studied lactoferrin effectiveness in 8%
mucus gels.
Although the iron content (42.9 M) of 8% mucus was in the
range reported for CF mucus (17–134 M) (30), we prepared
low-iron mucus (8.4–12.3 M) so that the iron-chelating capacity
of physiological concentrations of lactoferrin (1 mg/ml, 22 M)
(31) was not exceeded. Pseudomonas formed macrocolonies in
low-iron mucus (Fig. 5A), and this process was not inhibited by
lactoferrin addition in concentrations predicted to be sufficient
to chelate all iron (1 and 10 mg/ml) (Fig. 5B). A high concen-
tration of conalbumin (10 mg/ml), reported to inhibit Pseudo-
monas macrocolony development (7), also had no effect on
macrocolony formation in concentrated airway mucus (Fig. 5C).
These results appear to mimic the condition in CF airways in vivo
when biofilms form, despite apparently high concentrations of
lactoferrin (2, 32). We also measured diffusion of fluorescently
labeled lactoferrin from a point source in shallow chambers filled
with either 2.5% or 8% mucus, mimicking submucosal gland
Fig. 3. Variables influencing macrocolony development in mucus. (A) P.
aeruginosa macrocolony formation in CF mucus. GFP-PAO1 (5  103 cfu)
deposited in CF mucus exhibited macrocolony formation in 8% mucus (ii) but
not in 2.5% mucus (i) 48 h after inoculation. (Scale bar  200 m.) (B) Effects
of lasI gene mutation. Wild-type PAO1 (i) but not lasI mutants (ii) developed
macrocolonies 48 h after inoculation with 5  103 bacteria. (Scale bar  200
m.) x–y (iii) and x–z (iv) scanning by confocal microscopy detected homoge-
neous distribution of planktonic single bacteria (lasI mutant) within mucus of
8% solids. (Scale bar  50 m.) The defective macrocolony formation was
rescued by addition of 10 M 3-oxo C12 HSL (v). (Scale bar  200 m.)
Fig. 4. Mechanisms of macrocolony development. (A) Mean squared dis-
placement of 1-m beads in 2.5% and 8% mucus. (B) Mean squared displace-
ment times radius of 200-nm, 1-m, and 3-m beads in 2.5% and 8% mucus.
(C) P. aeruginosa motility in mucus of 2.5% and 8% solids. (D) Diffusion of
3-oxo C12 HSL in 2.5% vs. 8% mucus; n  6.








secretion of lactoferrin into a mucus layer in the normal and CF
airways. Like HSL, lactoferrin diffusion was markedly slowed in
8% mucus gels (Fig. 5D).
Discussion
Our goal was to establish a simple model that mimics the
interactions of inhaled Pseudomonas with a central feature of the
CF lung, i.e., dehydrated, adherent mucus plaques (33). This
simple model revealed two aspects of concentrated mucus gels
characteristic of CF that may yield insights into the mode of P.
aeruginosa growth in the CF lung.
First, our data suggest that the concentrated mucus (8%),
regardless of source (i.e., CF vs. normal), generates a unique
environment in which bacteria are confined spatially so that
multiplication at a site of droplet deposition outstrips the
capacity of bacteria to leave the site by their normal means of
motility. The mucin concentration-specific effect on mucus mesh
size produces high local concentrations of autoinducers by
limiting 3-oxo C12 HSL diffusion away from the site of bacterial
replication, producing an environment that favors biofilm (mac-
rocolony) formation. Note that our experimental system is
designed to mimic the acquisition of infection in CF, i.e., we use
concentrated mucus from noninfected cultures exposed to drop-
lets containing bacteria. Dawson et al. (28), however, have used
the microbead technology to characterize biophysical features of
infected CF sputum. The identification of similar biophysical
properties suggests that infected, but still concentrated, CF
sputum also favors biofilm formation.
Second, multiple features of thickened CF mucus gels may
account for the ineffectiveness of a major endogenous antimi-
crobial substance in mucus, i.e., lactoferrin, to inhibit biofilm
formation in CF airway mucus as compared with its effectiveness
in flow-through chambers/abiotic surfaces. First, the reported
effects of lactoferrin to increase twitch motility in flow chambers
(7) are likely less important when motility is restricted by a mucus
gel of 8% solids rather than intrinsic bacterial motility. Second,
lactoferrin may inhibit bacterial growth/biofilms by direct inter-
actions with bacteria. This activity may be reduced in concen-
trated mucus as lactoferrin becomes bound (or diffusion limited)
and not freely available. Third, in vivo in CF airways, lactoferrin
secreted from submucosal glands would be predicted (Fig. 5D)
to diffuse poorly into the stationary thickened mucus, containing
P. aeruginosa biofilms, on airway surfaces.
Pseudomonas infection leads to a deterioration in the clinical
course of CF patients (34–36), but the unique predisposing
features that produce a persistent Pseudomonas infection in the
CF airway have been unclear. Previously, it had been reported
that ASL hyperabsorption in CF produces periciliary liquid
depletion and mucus stasis that favor acquisition of infection (1,
33). Our data suggest that this common event, i.e., ASL hyper-
absorption, produces a concentrated mucus gel that promotes P.
aeruginosa to grow as macrocolony-like biofilms due to the
physical properties of a tight mucin mesh, and increased vis-
coelastic properties that limit bacterial motility and 3-oxo C12
HSL diffusion. Further, our data add to an understanding of how
concentrated, dehydrated CF mucus impairs the host defense.
Previous studies have shown that the reduced mesh pore size
produced by mucus concentration reduces the effectiveness of
neutrophils to penetrate and kill P. aeruginosa residing in
concentrated, but not ‘‘normal,’’ mucus gels (37). The present
study demonstrates that the activity of a soluble host defense
factor, i.e., lactoferrin, is also degraded in concentrated, CF-like
gels. Among the therapies suggested by these studies, perhaps
the most direct is to rehydrate thickened mucus to normalize
mesh pore size.
Methods
Preparation of Concentrated Mucus. Human tracheo–bronchial
epithelial cells (CF and normal) were isolated and cultured
under air–liquid conditions as previously described (38). Mucus
harvested from 200 concurrent cultures was pooled and stored
at 4°C. The mucus samples were placed in dialysis tubes (mo-
lecular weight of CO  3,500; Spectrum Laboratories, Rancho
Dominguez, CA) and concentrated with a polymer absorbent
(Spectra/Gel; Spectrum Laboratories) for 1–5 days at 4°C. The
concentrated mucus was dialyzed against PBS (3 liters, four
times) containing 500 M MgCl2 and 800 M CaCl2 at 4°C. The
percent dry weight of mucus was calculated by measuring the wet
and dry weights with a microbalance before and after drying the
sample at 80°C overnight (39). Because of the difficulty in
depleting harvested mucus samples of exact volumes, a 10%
difference from the target concentration was allowed.
Determination of Mucin Concentration. The concentration of mu-
cins in mucus was assessed by differential refractometry (40). A
500-l sample was chromatographed on a Sepharose CL-2B
column (Amersham Pharmacia, Piscataway, NJ), which was
eluted with 200 mM sodium chloride/10 mM EDTA at a flow
rate 0.3 ml/min. The column effluent was passed through an
in-line Dawn EOS laser photometer coupled to a Wyatt/Optilab
DSP inferometric refractometer to measure light scattering and
sample concentration, respectively. The concentration of the
mucins was calculated by integrating the refractive index peak
associated with the material eluted in the void volume of the
column and employing a value for the refractive-index increment
(dn/dc) of 0.165 ml/g, which has been measured previously at 650
nm. The reproducibility of this procedure was within 5%.
Preparation of Bacteria and Autoinducers 3-oxo C12 HSL. P. aerugi-
nosa PAO1 (41), an isogenic lasI mutant (42), and a nonpiliated,
nonflagellated mutant (PAO-NPNF, kind gift from A. Prince)
were maintained on trypticase soy agar (Becton-Dickinson,
Sparks, MD) with appropriate antibiotics as needed (gentamy-
cin, 50 g/ml; Sigma). In addition, the plasmid pTdK-gfp (43) was
introduced by using electroporation (44) into these strains to
allow visualization of the bacteria. Overnight cultures of bacteria
Fig. 5. Absence of effects of lactoferrin on P. aeruginosa macrocolony
development in 8% mucus. Mucus was infected with 5  103 PAO1 as above,
and images were obtained by fluorescence microscopy 48 h later. (A) Low-iron
mucus control. (B) Low-iron mucus with 10 mg/ml lactoferrin. (C) Low-iron
mucus with 10 mg/ml conalbumin. (Scale bar  200 m.) (D) Diffusion of
fluorescently labeled lactoferrin in mucus. Fluorescence intensity ratio be-
tween highest and lowest regions in 2.5% vs. 8% mucus after lactoferrin
deposition as a point source was measured at 0, 3, 18, 24, and 48 h; n  3.
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were prepared for each assay with appropriate antibiotics when
needed (200 gml carbenicillin; Sigma). Autoinducer 3-oxo C12
HSL was synthesized and purified as previously reported (45)
and used as received.
Bacterial Culture in Mucus. To measure bacterial growth, 5  103
PAO1 were deposited on 270 l of mucus of varying concen-
trations in a plastic f lat chamber (1 mm in depth, 20 mm in
diameter) with or without a plastic lid. At 0, 6, 24, 48, and 72 h
later, bacteria in mucus were collected, diluted with PBS con-
taining 10 mM DTT, and plated on tryptic soy agar plates after
serial dilution. DTT treatment disaggregated the bacteria and
did not affect the viability of the bacteria.
To measure macrocolony development, 5  103 GFP-PAO1
were deposited onto mucus in the same plastic chambers and
observed by epifluorescent (Nikon TE300) or confocal (Zeiss
510) microscopy at 24, 48, and 72 h. For quantitation, five
pictures for each culture were digitally acquired and analyzed by
using the Metamorph image analysis system (Universal Image).
A bacterial colony was defined as a structure with a discrete edge
and size larger than 50 m2. Dead bacteria were stained at day
3 with 5 g/ml propidium iodide (molecular probes), which is
impermeable into intact bacteria. The resolution of these images
was too low to determine the internal structures of the biofilms.
Measurement of Oxygen. Oxygen partial pressure was measured
with an oxygen-sensitive fluorescent probe, the ruthenium com-
plex Tris(4,7-diphenyl-1,10-phenanthroline)-ruthenium
hexafluorophosphate (Sigma–Aldrich, St. Louis, MO). The ru-
thenium complex, adsorbed onto silica particles (1–5 m;
Sigma), was embedded in silicone rubber (silicone II; GE) and
pasted onto glass slides (46). The coated glass slides were then
used as the bottom of the bacterial culture chamber (Fig. 1B).
Fluorescence intensity was measured by confocal microscopy at
3, 6, 9, 24, and 48 h to calculate oxygen partial pressure. Each
glass-slide probe was calibrated with uninfected mucus for 21%
pO2 and with saturated sodium sulfite solution for 0% pO2 at
time 0. At each time point, artificial f luctuation of fluorescence
intensity, caused partly by laser power instability, was corrected
by measuring fluorescence intensity of distilled water (pO2 
21%) and sodium sulfite solution (pO2  0%).
Bacterial Motility in Mucus. GFP-PAO1 was deposited onto mucus
(2.5% and 8% solids) in the plastic chamber and photographed
by epifluorescent microscope with a 40 objective at an interval
of 0.25–1 sec. Only planktonic bacteria observed to undergo
unidirectional motion were used to calculate bacterial velocity.
Diffusion of 3-oxo C12 HSL in Mucus. A 10 mM 3-oxo C12 HSL
solution in DMSO was mixed with a 10 volume of mucus (2.5%
or 8% solids) to prepare the source of HSL. Capillary tubes (40
mm in length, 25-l capacity; Statspin Technologies, Norwood,
MA) containing 2.5% or 8% mucus were placed in the tubes
containing HSL in an equivalent mucus concentration and had
the free end sealed with silicone. After 24 h at 37°C, the capillary
tubes with mucus were frozen and cut into eight pieces to
measure the 3-oxo C12 HSL concentration in each section.
Autoinducer was extracted from each mucus cross-section by
using ethyl acetate (J. T. Baker) acidified with 0.001% glacial acetic
acid (J. T. Baker) as previously described (47) with the following
modifications. Twice the sample volume of acidified ethyl acetate
was added to the mucus sample suspended in 100 l of PBS in a 1.5-
ml Eppendorf tube. Samples were subsequently vortexed for 3 min,
and the two phases were separated by centrifugation at 10,000  g
for 10 min. The ethyl acetate phase was then transferred to a clean
1.5-ml Eppendorf tube. The extraction process was repeated once
more, and the ethyl acetate phases were pooled. The concentration
of 3-oxo C12 HSL was assayed in each sample by using the previously
described bioassay (47). The number of moles of 3-oxo C12 HSL in
each sample was then normalized to the total number of moles of
3-oxo C12 HSL extracted from all samples in each assay and
reported as percent occurrence. Each experiment was repeated in
quadruplicate.
The diffusion coefficient was calculated by fitting a Gaussian
to data collected for the distribution of radioactive molecules in
1D dimension. The distribution was defined by:
 (x , t)  0e
x  x02
2Dt [1]
(48), where D is the diffusion coefficient and t is the time over
which diffusion has occurred.
Microbead Rheology. MyOne 1-m-diameter carboxylated beads
(Dynal), 2.9-m-diameter yellow-green fluorescent carboxy-
lated beads (Polysciences), and 200-nm-diameter red fluorescent
carboxylated beads (Polysciences) were added to mucus samples,
and their diffusion was recorded at 120 frames per second with
a Pulnix PTM-6710 8-bit grayscale video camera (Jai-Pulnix) on
a Nikon Eclipse TE2000-E inverted microscope with a 60
water immersion objective (NA  1.2). Beads were tracked in
postprocessing by using Video Spot Tracker (software available
for free download at http://www.cs.unc.edu/Research/nano/
cismm/download/spottracker/videospottracker.html). The av-
erage noise signal of a fixed bead was 5 nm.
Eq. 1 is used to calculate the mean squared displacement of
particles undergoing Brownian motion within the fluid, r 2(),
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ranges between 0 for purely elastic f luids and 1 for purely viscous
fluids and is used to characterize the degree of elasticity
measured in a fluid (24).
Effects of Lactoferrin on Pseudomonas Macrocolony Formation. GFP-
PAO1 was deposited onto concentrated mucus of 8% solids con-
taining lactoferrin (iron-unsaturated, Sigma) or conalbumin
(Sigma) (final concentrations, 1 and 10 mg/ml). Macrocolony
formation was monitored as mentioned above at days 1, 2, and 3.
Measurement of Iron in Mucus Samples. Total iron content of mucus
samples was measured after trichloroacetic acid precipitation
(20%, 1:1) with a flame atomic absorption spectrometer (49)
(AAnalyst 100; Perkin–Elmer, Wellesley, MA).
Diffusion of Lactoferrin. One microliter of human lactoferrin
solution labeled with Oregon Green (1 mg/ml; Molecular
Probes) was deposited at four points onto an open chamber
containing 270 l of mucus (2.5% or 8% solids). After 0, 3, 18,
24, and 48 h of incubation at 37°C, fluorescent intensity was
measured at the brightest and dimmest points, by using Nikon
TE300 with a 4 objective. Fluorescence intensities were nor-
malized against control images of mucus with no lactoferrin.
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